News Sentiment

DSGN sentiment intelligence

Design Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 15.19 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-2.9% over one week, +38.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Myotonic Dystrophy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Bioscien

Market Reaction

Balanced read

70/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -2.9% Price reacting lower
Trend fit Trend active 38.5% over four weeks
Fair value 164.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 26
Neutral 34
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 9
TradingView 6
Investing.com 4
TradingKey 4
GlobeNewswire 3
Barchart.com 2
marketscreener.com 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 17
Analyst action 5
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 61
Stock Titan Direct company coverage

Director at Design Therapeutics (DSGN) awarded options on 30,000 shares

Design Therapeutics (DSGN) director Justin D. Gover has been granted stock options for 30,000 shares of common stock. These options have an exercise price of $10.55 per share and an expiration date of June 8, 2036. The shares will vest in equal monthly installments over 12 months

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Design Therapeutics (DSGN) director awarded 30,000 options at $10.55 strike

Design Therapeutics (DSGN) director Rodney W. Lappe was granted 30,000 stock options with an exercise price of $10.55 per share, expiring on June 8, 2036. The options will vest in equal monthly installments over 12 months following June 9, 2026, or fully by the company's next ann

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Director at Design Therapeutics (DSGN) awarded 30,000 stock options

Design Therapeutics (DSGN) director Heather A. Berger was granted 30,000 stock options with an exercise price of $10.55 per share. These options will vest in equal monthly installments over 12 months following June 9, 2026, or fully vest by the company's next annual meeting of st

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] Design Therapeutics, Inc. Insider Trading Activity

Design Therapeutics, Inc. director John P. Schmid was granted 30,000 stock options with an exercise price of $10.55 per share, expiring in 2036. These options will vest in equal monthly installments over 12 months starting June 9, 2026, or fully vest by the company's next annual

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 20:40
Source
Stock Titan